Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe
USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5 million) in milestone payments from partner Astellas Pharma (TYO: 4503) of Japan, for the first sales of Dificlir (fidaxomicin) tablets in Europe. Under a 2011 agreement, Astellas was granted the rights to develop and commercialize Dificlir in Europe and certain other countries including the Middle East, Africa and the Commonwealth of Independent States (CIS).
Optimer is eligible to receive milestone payments of up to $224 million including a $68 million upfront cash payment. Astellas will pay tiered double-digit royalties on net sales of Dificlir. Under the deal, Astellas will bear all costs related to the development, manufacturing and commercialization of the product in the covered areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze